Buy Generic Lenalidomide Online

Description

What is Lenalidomide (Mylomid)? 

Mylomid (Lenalidomide) is used to treat a certain type of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells). Lenalidomide is also used along with dexamethasone to treat people with multiple myeloma (a type of cancer of the bone marrow). It is also used to treat people with multiple myeloma after a hematopoietic stem-cell transplant (HSCT; procedure in which certain blood cells are removed from the body and then returned to the body). Lenalidomide is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) who have been treated with bortezomib and at least one other medication.

Lenalidomide should not be used to treat people with chronic lymphocytic leukemia (a type of cancer of the white blood cells that gets worse slowly over time) unless they are participating in a clinical trial (research study to see whether a medication may be used safely and effectively to treat a certain condition). Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. To know more about Lenalidomide please visit here.

Why should you buy the generic Lenalidomide online?

First of all generic Mylomid is very affordable version of Lenalidomide for  multiple myeloma patients.  It is a verified generic version of Revlimid. Drug International Limited manufacture this generic version in Bangladesh. It is one of the renowned pharmaceutical companies who mostly made local medicine in Bangladesh. After the Directorate General of Drug Administration of Bangladesh approves to manufacture Lenalidomide, they started to make it and sell it all over the world where generic medicine is allowed to use.

It is the 2nd generic version of Revlimid which is selling regularly all over the world. It is also 99% cheaper than the brand version of Lenalidomide. Which cost you less than 200 dollars. There are some more medicine available for multiple myeloma patients. To know more you can visit our shop page.

COMPOSITION

Mylomid-10: Each capsule contains Lenalidomide INN 10 mg.
Mylomid-25: Each capsule contains Lenalidomide INN 25 mg.

Where To Buy Lenalidomide Online

If you are interested to buy generic lenalidomide online you can contact us through email, WhatsApp, or WeChat. Our support agent will help you to know more details about generic lenalidomide (Mylomid). Visit our shop page to know more details.

Cost Of Lenalidomide In India

Lenalidomide is also known as Revlimid is an expensive medicine for multiple myeloma and myelodysplastic syndromes. But The cost of lenalidomide in India and Bangladesh is very affordable. We offer generic lenalidomide 10 mg 28 capsules for only 135 USD and 25 mg 30 capsules cost only 150 USD. If you are interested to buy lenalidomide online from us please contact our support team.

Mechanism of Action

Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of Lenalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of the drug, substrate proteins (including Aiolos, Ikaros, and CK1α) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including MM. Immunomodulatory properties of Lenalidomide include increased number and activation of T cells and natural killer (NK) cells leading to direct and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via increased secretion of interleukin-2 and interferon-gamma, increased numbers of NKT cells, and inhibition of pro inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In MM cells, the combination of Lenalidomide and Dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.

INDICATIONS

Multiple Myeloma:

Lenalidomide in combination with Dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM). Lenalidomide is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). Myelodysplastic Syndromes: Lenalidomide is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Mantle Cell Lymphoma:

Lenalidomide is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib.

Follicular Lymphoma:

Lenalidomide in combination with a Rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).

Marginal Zone Lymphoma:

Lenalidomide in combination with a Rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). Limitations of Use: Lenalidomide is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials.

DOSAGE AND ADMINISTRATION

Recommended Dosage for Multiple Myeloma:

Lenalidomide Combination Therapy:

The recommended starting dose of Lenalidomide is 25 mg orally once daily on Days 1-21 of repeated 28-day cycles in combination with Dexamethasone. For patients greater than 75 years old, the starting dose of Dexamethasone may be reduced. Treatment should be continued until disease progression or unacceptable toxicity. In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a Lenalidomide-containing therapy. Lenalidomide

Maintenance Therapy Following Auto-HSCT:

Following auto-HSCT, initiate Lenalidomide maintenance therapy after adequate hematologic recovery (ANC at least 1000/mcL and/or platelet counts at least 75,000/mcL). The recommended starting dose of Lenalidomide is 10 mg once daily continuously (Days 1-28 of repeated 28-day cycles) until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.

Recommended Dosage for Myelodysplastic Syndromes:

The recommended starting dose of Lenalidomide is 10 mg daily. Treatment is continued or modified based upon clinical and laboratory findings. Continue treatment until disease progression or unacceptable toxicity.

Recommended Dosage for Mantle Cell Lymphoma:

The recommended starting dose of Lenalidomide is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma. Treatment should be continued until disease progression or unacceptable toxicity. Treatment is continued, modified or discontinued based upon clinical and laboratory findings.

Recommended Dosage for Follicular Lymphoma or Marginal Zone Lymphoma:

The recommended starting dose of Lenalidomide is 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles of treatment in combination with a Rituximab-product.

Lenalidomide Combination Therapy for MM:

For CLcr of 30 to 60 mL/min, consider escalating the dose to 15 mg after 2 cycles if the patient tolerates the 10 mg dose of Lenalidomide without dose-limiting toxicity

ADMINISTRATION

Patients should be advised to take Lenalidomide orally at about the same time each day, either with or without food. Patients should be advised to swallow Lenalidomide capsules whole with water and not to open, break, or chew them.

ADVERSE EFFECTS

Embryo-fetal toxicity, hematologic toxicity, venous and arterial thromboembolism, increased mortality in patients with CLL, second primary malignancies, hepatotoxicity, severe cutareous reaction tumor lysis syndrome, tumor flare reactions, impaired stem cell mobilization, thyroid disorders. early mortality in patients with MCL, hypersensitivity

CONTRAINDICATIONS

None

Pregnancy

Lenalidomide can cause fetal harm when administered to a pregnant female. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus.

Severe Hypersensitivity Reactions

Lenalidomide is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to Lenalidomide.

DRUG INTERACTIONS

Digoxin:

When Digoxin was co-administered with multiple doses of Lenalidomide (10 mg/day) the Digoxin Cmax and AUCinf were increased by 14%. Periodic monitoring of Digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, is recommended during administration of Lenalidomide.

PRECAUTIONS

Lenalidomide REMS Program: Because of the embryo-fetal risk, Lenalidomide is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), the Lenalidomide REMS program.

Required components of the Lenalidomide REMS program include the following:

• Prescribers must be certified with the Lenalidomide REMS program by enrolling and complying with the REMS requirements.

• Patients must sign a Patient-Physician agreement form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements and males must comply with contraception requirements.

• Pharmacies must be certified with the Lenalidomide REMS program, must only dispense to patients who are authorized to receive Lenalidomide, and comply with REMS requirements.

Use in Pregnancy:

Based on the mechanism of action, Lenalidomide can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy.

Use in Lactation:

There is no information regarding the presence of lenalidomide in human milk, the effects of Lenalidomide on the breastfed infant, or the effects of Lenalidomide on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed infants from Lenalidomide, advise women not to breastfeed during treatment with
Lenalidomide.

OVERDOSE:

There is no specific experience in the management of Lenalidomide overdose in patients with MM, MDS, or MCL.

Lenalidomide Generic Manufacturers

There are few Pharmactuicals companies that manufacture generic lenalidomide in Bangladesh.  Drug International Limited is one of them. Renta Pharmactuicals and Beacon Pharma are also lenalidomide generic manufacturers in Bangladesh.

PHARMACEUTICAL INFORMATION

Storage:

Store below 30 degrees in a dry place. Protect from light. Keep out of the reach of children.

Packing:

Mylomid-10: Each box contains 28 capsules in alu-alu blister pack.
Mylomid-25: Each box contains 30 capsules in alu-alu blister pack.